Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | DRD4 | P21917 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 5/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427031 | 0.87 | MMP12 (0.39) | MMP12PARP1DRD2DRD4DRD3 | |
| SCHEMBL24427465 | 0.74 | MMP12 (0.45) | MMP12PARP1DRD2DRD4DRD3 | |
| SCHEMBL3139145 | 0.74 | BRD4 (0.44) | PKMBRD4HTR1AHTR1DHTR1B | |
| SCHEMBL4182404 | 0.74 | SMYD3 (0.43) | PARP1DRD2HTR1AHTR1DHTR1B | |
| SCHEMBL1851941 | 0.70 | CREBBP (0.58) | MMP12PARP1DRD2NR3C2PKM | |
| SCHEMBL8301820 | 0.69 | MMP12 (0.50) | MMP12PARP1DRD2DRD4DRD3 | |
| SCHEMBL8197651 | 0.68 | MMP12 (0.45) | MMP12PARP1DRD2DRD4DRD3 | |
| SCHEMBL8198141 | 0.68 | MMP12 (0.42) | MMP12PARP1DRD2DRD4DRD3 | |
| SCHEMBL11912374 | 0.66 | DRD2 (0.42) | MMP12PARP1DRD2DRD4DRD3 | |
| SCHEMBL8307023 | 0.66 | DRD2 (0.38) | PARP1DRD2DRD4DRD3NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| CN-101048414-B | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD | 2011-09-07 | — | — | CN | disclosed |
| CN-101048414-A | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD (GB) | 2007-10-03 | — | — | CN | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | MMP12 4861/4885PARP1 1100/4885DRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.